| abstract |
The task was to develop new antipsychotics with subtypselective and / or novel affinity profiles on the dopamine receptor subtypes, which achieve effective blocking of the mesolimbic-dopaminergic system but do not or not significantly affect the nigro-striatal system and which, if possible, do not affect other undesired ones Show side effects. According to the invention, a compound of general formula I, z. As a dibenz [d, g] azecine, Thienobenzazecin- or Furobenzazecin derivative used. The new dopamine antagonists are used as antipsychotics for the treatment of schizophrenia. |